BAFIERTAM
Peakmonomethyl fumarate
NDAORALCAPSULE, DELAYED RELEASE
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
BAFIERTAM (monomethyl fumarate) is (mmf) exerts its therapeutic effect in multiple sclerosis is unknown. Approved for relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease and 2 more indications. First approved in 2020.
Drug data last refreshed 1h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BAFIERTAM (monomethyl fumarate) is an oral delayed-release capsule approved in 2020 for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug activates the Nrf2 pathway to modulate cellular responses to oxidative stress and has been identified as a nicotinic acid receptor agonist, though its precise therapeutic mechanism in MS remains incompletely understood.
$0.005BPart D
Peak8.4 years to LOEDrug is at peak lifecycle stage with modest Part D uptake (588 claims in 2023), suggesting stable but limited market penetration; brand team likely sized for maintenance rather than growth expansion.
Mechanism of Action
(MMF) exerts its therapeutic effect in multiple sclerosis is unknown. MMF has been shown to activate the Nuclear factor (erythroid-derived 2) like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.